Inspire Medical Systems, Inc. (NYSE:INSP) is a leading medical technology company. On May 5, 2026, the analyst firm Piper Sandler downgraded its rating on Inspire Medical Systems, Inc.. This change in investor outlook occurred even as the company released strong quarterly financial results, creating a mixed signal for investors.
Piper Sandler adjusted its rating on the stock from Overweight to Neutral. An "Overweight" rating suggests an analyst believes the stock will perform better than the market, while "Neutral" suggests it will perform in line with the market. At the time of this downgrade, Inspire Medical Systems, Inc.'s stock price was $54.84.
Despite the downgrade, Inspire Medical Systems, Inc. announced strong first-quarter results. The company reported an adjusted diluted earnings per share (EPS) of $0.10. As highlighted by Zacks, this figure significantly beat the consensus estimate, which had predicted a loss of $0.36 per share. EPS represents the company's profit allocated to each outstanding share of stock.
Revenue for the quarter ending in March 2026 was over $204.5 million, a 1.6% increase from the previous year. This performance also surpassed revenue estimates by nearly 3%. According to a report from GlobeNewswire, this marks the fourth consecutive quarter that Inspire Medical Systems, Inc. has exceeded both earnings and revenue expectations.
The company also shows positive cash generation, with an operating cash flow of $12.8 million for the quarter. CEO Tim Herbert stated the company is focusing on revenue-generating activities and disciplined cost management. This strategy aims to support the company's long-term growth while maintaining financial health.
